Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$3.83
▲ $0.29 (+8.2%)
Market data updated: 09/20 01:57 AM
Fundamentals updated: 09/19/2026
News analyzed: 09/20/2026
Market Cap
$2.05B
Day Range
$3.50 - $3.83
52-Week Range
$2.77 - $7.18
Beta
—
Next Earnings
03.11.2026
Support
$2.84
Resistance
$3.83
RXRX is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-22.3% (1Y)
Strengths: 18/31 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 26.9%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$20.97 vs. price $3.83 (-647.6%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
59
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
today · $3.83
Evidence: FOMO score jumped from 30 to 62 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
51
Quality
63
Value
38
Momentum
88
Risk
46
Sentiment
92
Fundamental
31
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **Recursion Pharmaceuticals** has primarily focused on its **stock performance and clinical pipeline expansion**, particularly in oncology and rare diseases. The company’s share price has seen fluctuations tied to earnings reports and positive trial results, with analysts highlighting its programs like **REC-4881** as potential growth drivers. Some headlines also mention broader industry trends, including comparisons with peers like Tempus AI and CRISPR Therapeutics, though Recursion’s specific updates remain sparse. The focus remains on its long-term potential amid biotech sector volatility.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Recursion Pharmaceuticals, Inc.. News trend score: 92. Reason: 9 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
54
🎯 Conviction (vs. Emotion)
42
Psychology
100
Fundamentals
31
Technical
88
Valuation
38
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+19%
Market Narrative
78
Fundamental Reality
42
Narrative Gap
+36
🧠 StockIQ Psychologist
The market behavior for RXRX suggests a dominant **confirmation bias**, where investors prioritize narrative-driven optimism (+69 narrative score) over weak fundamentals (reality score 38). Overconfidence in price momentum (+4.5% vs. +0.1% EPS growth) and FOMO (driven by perfect sentiment) further amplify this disconnect. The key open question is whether fundamentals will eventually force a reassessment—or if traders will sustain the gap. The lack of anchoring or loss aversion signals suggests complacency, not urgency. Herding remains minimal, as the stock underperformed peers today.
Updated: 09/09/2026, 07:24 AM
What could change this?
👥 What the crowd believes
"Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts."
"Recursion, Novavax and Crispr Therapeutics slip in premarket trading after surging Wednesday on positive cancer therapy trial results."
"4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma."
"Morgan Stanley Adjusts PT on Recursion Pharmaceuticals to $5.30 From $5.50, Keeps Equalweight Rating."
🧠 Market Brain events driving this
📈 9D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Samuel Armstrong Nelson — 7/100
🗣️ Why do they disagree?
This stock sparks a sharp divide among methodologies, with some legendary investors seeing strong fundamentals while others warn of speculative risks or overvaluation. Walter Bagehot and Benjamin Graham (both in his defensive and enterprising forms) rate it highly, praising its liquidity and value—suggesting it could weather crises or offer a disciplined bargain. Meanwhile, growth-focused thinkers like Peter Lynch see upside potential, while more cautious voices like Howard Marks and Gerald Loeb flag concerns about inflated expectations or excessive risk. At the extremes, Morgan Housel and Thorstein Veblen dismiss it outright, viewing it as either volatile or driven by speculative hype rather than sustainable value. The contrast reflects a tension between value, growth, and speculative momentum—some see stability and opportunity, while others see a speculative bubble or a late-stage investment.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 84
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 75
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 73
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 64
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 53
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 52
Some discount, but not the deep 'net-net' bargain Graham's enterprising bar sets
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 50
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 48
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 46
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 42
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 39
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 39
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 37
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 21
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 7
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (10 bullish · 1 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
5.0%
Operating Margin
-880.9%
Net Margin
-863.4%
EBITDA Margin
—
ROE
-57.0%
ROA
-43.7%
ROIC
—
EPS
-$1.44
Cash
$743.29M
Total Debt
—
Current Ratio
5.50
Debt/Equity
0.02
How is Fair Value calculated? →
Current Price
$3.83
Estimated Fair Value (DCF)
-$20.97
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-647.6%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
23.6%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 23.6% | $-467.55M | $-428.95M |
| 2 | 18.3% | $-553.23M | $-465.64M |
| 3 | 13.1% | $-625.43M | $-482.95M |
| 4 | 7.8% | $-674.06M | $-477.52M |
| 5 | 2.5% | $-690.91M | $-449.04M |
Base FCF (last actual year)
$-378.28M
Terminal Value
$-10.90B
Present Value of Terminal Value
$-7.08B
Enterprise Value
$-9.39B
Net Debt
$0
Equity Value
$-9.39B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$2.14
Tangible Book Value per Share (Tangible NAV)
$1.56
Sentiment based on basic keywords (not AI) — 9 positive, 9 neutral, 2 negative out of the last 20 articles.
Yahoo · 19.9.2026
Yahoo · 18.9.2026
Benzinga · 17.9.2026
Yahoo · 16.9.2026
SeekingAlpha · 15.9.2026
Yahoo · 10.9.2026
Zacks · 10.9.2026
Yahoo · 8.9.2026
Motley Fool · 8.9.2026
SeekingAlpha · 5.9.2026
Yahoo · 4.9.2026
Zacks · 4.9.2026
Yahoo · 3.9.2026
Zacks · 3.9.2026
SeekingAlpha · 20.8.2026
Benzinga · 20.8.2026
Zacks · 18.8.2026
MT Newswires · 17.8.2026
Zacks · 17.8.2026
MT Newswires · 17.8.2026
Recursion Pharmaceuticals, Inc. (RXRX) currently has a StockIQ AI score of 59/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
RXRX currently scores 59/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, RXRX's estimated fair value is -$20.97, which is 647.6% below the current price of $3.83. This is one valuation model among several signals in the fair-value category, not a price target.
RXRX's technical score is 88/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 26.9%; Operating margin is stable or improving over time; Debt/equity: 0.02.
Based on the real signals StockIQ computed: Estimated fair value: -$20.97 vs. price $3.83 (-647.6%); Operating margin: -880.9% (negative); Net margin: -863.4% (negative).
StockIQ has no recorded dividend payment history for RXRX.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 7 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Borgeson Blake | Open Market Sale | 1.9.2026 | 30,000 | -30,000 | $3.34 |
| Taylor Ben R | Tax Withholding in Shares | 17.8.2026 | 25,018 | -25,018 | $3.16 |
| Khan Najat | Tax Withholding in Shares | 17.8.2026 | 80,498 | -80,498 | $3.16 |
| Hallett David | Tax Withholding in Shares | 17.8.2026 | 26,657 | -26,657 | $3.16 |
| Borgeson Blake | Open Market Sale | 4.8.2026 | 30,000 | -30,000 | $3.25 |
| Borgeson Blake | Open Market Sale | 4.8.2026 | 6,188,287 | -30,000 | $3.25 |
| Borgeson Blake | Open Market Sale | 7.7.2026 | 40,000 | -40,000 | $3.96 |
| Borgeson Blake | Open Market Sale | 7.7.2026 | 6,218,287 | -40,000 | $3.96 |
| Li Dean Y | Grant/Award from Employer | 1.7.2026 | 3,747 | +3,747 | — |
| Dar Zavain | Grant/Award from Employer | 1.7.2026 | 5,109 | +5,109 | — |
| Li Dean Y | Grant/Award from Employer | 1.7.2026 | 1,473,329 | +3,747 | — |
| Dar Zavain | Grant/Award from Employer | 1.7.2026 | 240,764 | +5,109 | — |
| Bumpus Namandje | Open Market Sale | 18.6.2026 | 3,963 | -3,963 | $3.18 |
| Bumpus Namandje | Open Market Sale | 18.6.2026 | 127,632 | -3,963 | $3.18 |
| Dar Zavain | Grant/Award from Employer | 17.6.2026 | 88,424 | +88,424 | — |
| Sun Elaine D | Grant/Award from Employer | 17.6.2026 | 88,424 | +88,424 | — |
| Bumpus Namandje | Grant/Award from Employer | 17.6.2026 | 88,424 | +88,424 | — |
| Li Dean Y | Grant/Award from Employer | 17.6.2026 | 88,424 | +88,424 | — |
| Borgeson Blake | Grant/Award from Employer | 17.6.2026 | 88,424 | +88,424 | — |
| HERSHBERG ROBERT | Grant/Award from Employer | 17.6.2026 | 88,424 | +88,424 | — |
| Michor Franziska | Grant/Award from Employer | 17.6.2026 | 88,424 | +88,424 | — |
| HERSHBERG ROBERT | Grant/Award from Employer | 17.6.2026 | 162,156 | +88,424 | — |
| Bumpus Namandje | Grant/Award from Employer | 17.6.2026 | 131,595 | +88,424 | — |
| Li Dean Y | Grant/Award from Employer | 17.6.2026 | 1,469,582 | +88,424 | — |
| Dar Zavain | Grant/Award from Employer | 17.6.2026 | 235,655 | +88,424 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
179,145,796 shares short as of 2026-08-31 · vs. 180,771,459 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
58.2% of trading volume this week was short selling, vs. 53.7% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology